Oxalieva 50 mg Injection Exporter from India – Ernest Oncology USA

Comprehensive Guide to Oxalieva 50 mg Injection: Global Export & Distribution by Ernest Oncology

At Ernest Oncology (a division of Ernest Pharmaceutical Pvt. Ltd.), we are an internationally recognized exporter, bulk supplier, and distributor of critical oncology formulations. We specialize in the secure, compliant, and efficient supply of Oxalieva 50 mg Injection (Oxaliplatin Injection USP 50 mg/25 mL) to healthcare providers, hospitals, and pharmaceutical distributors worldwide, with targeted delivery networks in the USA, UK, Australia, and South Africa.

1. Product Information: Oxalieva 50 mg Injection

Oxalieva 50 mg Injection contains Oxaliplatin, a third-generation, platinum-based antineoplastic agent. It is utilized principally in combination chemotherapy regimens for its antineoplastic effects against various solid tumors.

Key Product Details

• Composition: Oxaliplatin USP 50 mg / 25 mL (2 mg/mL).

• Therapeutic Class: Platinum coordination complex / Antineoplastic agent.

• Formulation Type: Sterile concentrate for intravenous (IV) infusion.

• Storage Temperature: Store below 25°C. Protect from light. Do not freeze.

2. Mechanism of Action

Oxalieva functions as an alkylating-like agent that interferes with the genetic material of cancer cells:

• DNA Cross-linking: The compound enters the cell and binds to DNA, forming intra-strand and inter-strand cross-links.

• Inhibition of Synthesis: This cross-linking physically prevents DNA replication and transcription, arresting cell cycle progression.

• Apoptosis: The resulting DNA damage triggers cellular checkpoints, eventually resulting in programmed cell death (apoptosis) in rapidly dividing malignant cells.

3. Therapeutic Indications and Uses

Oxalieva 50 mg Injection is indicated for:

• Colorectal Cancer: Adjuvant treatment for stage III colon cancer following complete resection of the primary tumor.

• Metastatic Colorectal Cancer: Extensively used in the management of advanced/metastatic colorectal cancer, typically combined with 5-fluorouracil and leucovorin.

• Other Solid Tumors: Frequently utilized in specialized combination therapies (such as FOLFOX regimens) as directed by oncologists.

4. Administration and Safety Warnings

Administration

• Route of Administration: Intravenous (IV) infusion (usually administered over 2 to 6 hours) after dilution in appropriate solutions (such as 5% Dextrose).

• Compatibility Warning: Do not use needles or intravenous administration sets containing aluminum parts that may react with oxaliplatin, causing precipitation and loss of potency.

• Dosage Formulation: Administered under the direct supervision of a qualified oncology nurse or healthcare professional.

Side Effects & Precautions

• Common Side Effects: Nausea, vomiting, fatigue, loss of appetite, peripheral neuropathy, and alopecia (hair loss).

• Serious Risks: Severe bone marrow suppression (leading to thrombocytopenia, neutropenia, and anemia), nephrotoxicity (kidney damage), and ototoxicity.

• Contraindications: Hypersensitivity to platinum-containing compounds, severe bone marrow depression, active bleeding tumors, and pre-existing renal/hearing impairment

PRESCRIPTION MEDICINE IS : YES

Disclaimer: Oxalieva 50 mg Injection is a prescription chemotherapy drug. It must be administered strictly under the supervision of a qualified oncologist or healthcare professional in a clinical setting. Ernest Oncology supplies this medication in compliance with all applicable international pharmaceutical export laws and regulations.